SCHEMBL5223394

SCHEMBL5223394

CCOC(=O)CN(Cc1ccc(OCc2ccccc2)cc1)S(=O)(=O)N1CCCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.41
LTA4H P09960 1/20 0.41
TSPO P30536 1/20 0.41
RORC P51449 1/20 0.41
ALOX5 P09917 3/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
CNR2 P34972 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226093 0.95 MEN1 (0.43) L3MBTL1MAPTSMN1; SMN2LMNALTA4H
SCHEMBL5229675 0.92 POLB (0.42) L3MBTL1MAPTGAASMN1; SMN2LMNA
SCHEMBL5226874 0.89 MAPT (0.45) L3MBTL1MAPTGAASMN1; SMN2LMNA
SCHEMBL5229661 0.86 L3MBTL1 (0.44) L3MBTL1MAPTGAALMNAALDH1A1
SCHEMBL5263899 0.86 FFAR1 (0.49) MAPTLMNA
SCHEMBL5228007 0.84 MEN1 (0.47) MAPTGAASMN1; SMN2LMNAALDH1A1
SCHEMBL5224851 0.82 PPARG (0.53)
SCHEMBL5230147 0.81 PPARA (0.49) MAPTGAASMN1; SMN2LMNAALDH1A1
SCHEMBL5432331 0.81 FFAR1 (0.51) MAPTLMNA
SCHEMBL5429048 0.80 PPARG (0.44) MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 L3MBTL1 4766/4885MAPT 3705/4885GAA 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.